US45579U1097
US45579U1097
Indivior Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 1.239.000.000 | 1.188.000.000 | 4.3% |
| Cost of Revenue | 246.000.000 | 231.000.000 | 6.5% |
| Gross Profit | 993.000.000 | 957.000.000 | 3.8% |
| 728.000.000 | 723.000.000 | 0.7% | |
| Operating Income | 265.000.000 | 234.000.000 | 13.2% |
| Pretax Income | 239.000.000 | 20.000.000 | 1095.0% |
| Net Income Common Stockholders | 210.000.000 | 7.000.000 | 2900.0% |
| -- | -- | -- | |
| -- | -- | -- |